Don't miss these powerful industry presentations, bookmark the Industry Highlights channel
Join your fellow attendees for a vast array of options for extra education For additional programming details, please visit the Industry Highlights channel.
Visit the Industry Highlights Channel for additional programming and details about these planned events.
Saturday, Nov. 7
When Could CARDAMYST, the First and Only FDA-Approved Self-Administered Treatment for PSVT in Adults, Be Used in a Healthcare Professional’s Practice?
9:30–10:15 a.m. | Heart Theater 1
Supporter: Milestone Pharmaceuticals, Inc.
Putting the Pieces Together in ATTR-CM: A Practical Approach
9:30–10:15 a.m. | Learning Studio 3
Supporter: BridgeBio Pharma, Inc.
Empowering Champions: Cardiology’s Untapped Role in Stroke Prevention
9:30–10:15 a.m. | Learning Studio 4
Supporter: Medtronic, Inc.
Incretin-Based Therapies and the CKM Framework: Practical Considerations for Cardiovascular Practice
9:45–10:15 a.m. | CardioTalk 2
Supporter: Eli Lilly and Company
Beyond Medication: Advancing Hypertension Care With the Symplicity™ Blood Pressure Procedure
11:15 a.m.–Noon | Heart Theater 1
Supporter: Medtronic, Inc.
Aldosterone Dysregulation as a Driver of Uncontrolled and Resistant Hypertension, and CKM Risk: Cardiology, Endocrinology and Nephrology Clinical Perspectives
11:15 a.m.–Noon | Heart Theater 2
Supporter: Mineralys Therapeutics
Lp(a) Uncovered: Turning Inherited Risk Into Clinical Insight
11:15 a.m.–Noon | Learning Studio 1
Supporter: Amgen Inc.
Redemplo® (plozasiran): A Treatment to Lower Triglycerides for Adults With Familial Chylomicronemia Syndrome (FCS)
11:15 a.m.–Noon | Learning Studio 2
Supporter: Arrowhead Pharmaceuticals, Inc.
Advancing the ATTR-CM Journey Across the Care Continuum
11:15 a.m.–Noon | Learning Studio 3
Supporter: Pfizer Inc.
A Change of Heart: Rethinking Cardiovascular Care With
GLP-1RAs
11:15 a.m.–Noon | Learning Studio 4
Supporter: Novo Nordisk, Inc.
Cracking The Code: Uncover a Hidden Driver of Resistant Hypertension
11:15 a.m.–Noon | Learning Studio 5
Supporter: Corcept Therapeutics Inc.
Chasing Long-Term Cholesterol Control: Persistent Challenges and a Potential Role for One-Time Gene Editing Approaches
11:30 a.m.–12:45 p.m. | Industry Room N427D
Supporter: Eli Lilly and Company
Recurrent Pericarditis: Experts Perspectives on Disease Diagnosis and Management
12:30–1:15 p.m. | Heart Theater 1
Supporter: Kiniksa Pharmaceuticals Corporation
What We Don’t Do, What We Don’t See, What Comes Next: Device Therapy in Heart Failure
12:30–1:15 p.m. | Heart Theater 2
Supporter: Medtronic, Inc.
A Novel Aldosterone-Targeted Treatment for Patients With Uncontrolled Hypertension
12:30–1:15 p.m. | Learning Studio 1
Supporter: AstraZeneca
Unaddressed Risks: RAAS Dysregulation & the Role of Aldosterone in HF
12:30–1:15 p.m. | Learning Studio 2
Supporter: Boehringer Ingelheim Pharmaceuticals, Inc.
CRISPR-Based Gene Editing: Expanding Horizons in Cardiac Care
12:30–1:15 p.m. | Learning Studio 3
Supporter: Intellia Therapeutics, Inc.
Closing the Gap: Advancing Guideline-Directed Lipid Management and Treatment Intensification for High-Risk Patients
12:30–1:15 p.m. | Learning Studio 4
Supporter: Novartis Pharmaceutical Corporation
Implementation in Action: Closing the Gap in ASCVD
12:30–1:15 p.m. | Learning Studio 5
Supporter: Amgen Inc.
Advancing Lp(a) Care Through Shared Decision-Making
1:30–2 p.m. | CardioTalk 2
Supporter: (Heart) Implementation Science (QORA)
Beyond Traditional HCM: Understanding Cardiac Disease Progression in Friedreich Ataxia
1:45–2:30 p.m. | Heart Theater 1
Supporter: Lexeo Therapeutics, Inc.
Beyond Weight: Organ Crosstalk Throughout the Cardiometabolic Continuum
1:45–2:30 p.m. | Learning Studio 3
Supporter: Boehringer Ingelheim Pharmaceuticals, Inc.
New Data on ATTR-CM for Healthcare Providers From CARDIO-TTRansform
1:45–2:30 p.m. | Learning Studio 4
Supporter: AstraZeneca
Connecting at the Point of Care: Leveraging Industry Innovation With Integrated CKM Care Delivery
2–2:45 p.m. | Industry Room #N427D
Sponsor: (Heart) Cardiovascular-Kidney-Metabolic Syndrome
Seeing Women With Aortic Stenosis More Clearly: What SMART Reveals at 3 Years
3–3:30 p.m. | CardioTalk 2
Supporter: Medtronic, Inc.
Diagnosing, Staging and Treating CAD - The TRANSFORM Trial
3:15–4 p.m. | Learning Studio 3
Supporter: Cleerly, Inc
The Heart of CV Inflammation: Evidence and Evolving Science
3:15–4 p.m. | Learning Studio 4
Supporter: Novo Nordisk, Inc.
Detecting ATTR-CM Before Heart Failure: The Next Frontier in Precision Cardiomyopathy
3:15–4:30 p.m. | Industry Room N427D
Supporter: Pfizer Inc.
Sunday, Nov. 8
The Next Era in the Treatment of Hypertension
9:30–10:15 a.m. | Learning Studio 3
Supporter: Idorsia Pharmaceuticals Ltd.
Beyond the Heart: Why the Liver Matters in Cardiovascular Care
9:30-10:45 a.m. | Industry Room N427D
Supporter: Boehringer Ingelheim Pharmaceuticals, Inc
Factor XI Inhibition: The Next Era for Safer Stroke Prevention for Patients With Atrial Fibrillation
9:30–10:15 a.m. | Learning Studio 4
Supporter: Novartis Pharmaceutical Corporation
Measuring Quality in the Evaluation, Surveillance and Treatment of Aortic Stenosis | First Large-Scale Report From the American Heart Association Target: Aortic Stenosis Registry
9:45–10:15 a.m. | CardioTalk 2
Supporter: (HEART) Target: Aortic Stenosis
TRYNGOLZA: Expand What’s Possible With Triglyceride Reduction in Severe Hypertriglyceridemia (sHTG; TGs ≥500 mg/dL)
11:15 a.m.–Noon | Heart Theater 2
Supporter: Ionis Pharmaceuticals Inc.
Case-Based Approaches to Stroke Prevention
11:15 a.m.–Noon | Learning Studio 1
Supporter: Bristol Myers Squibb | Johnson & Johnson
From Clinical Clues to Treatment With a TTR Stabilizer: Exploring ATTR-CM Through Patient Cases
11:15 a.m.–Noon | Learning Studio 2
Supporter: BridgeBio Pharma, Inc.
Gene Therapy for the Failing Heart: Early Clinical Findings With Umiposgene Parvec (AB-1002)
11:15 a.m.–Noon | Learning Studio 3
Supporter: AskBio Inc.
Bridging Evidence and Practice: Insights Into LDL-C Management With a Nonstatin Therapy
11:15 a.m.–Noon | Learning Studio 4
Supporter: Novartis Pharmaceutical Corporation
Reviewing the Evidence for the Treatment of oHCM
11:15 a.m.–Noon | Learning Studio 5
Supporter: Cytokinetics, Inc.
Beyond the Lungs: RSV and Cardiovascular Risk in Adults
11:30 a.m.-12:45 p.m. | Industry Room N427D
Supporter: Pfizer Inc.
Initiating Evidence‑Based Therapies for HFpEF and HFmrEF – A Multidisciplinary Approach
12:30–1:15 p.m. | Heart Theater 1
Supporter: (Heart) Implementation Science (QORA)
Obstructive HCM: Translating Evidence Into Practice
12:30–1:15 p.m. | Heart Theater 2
Supporter: Bristol Myers Squibb
Mounjaro® (tirzepatide) Product Theater
12:30–1:15 p.m. | Learning Studio 1
Supporter: Eli Lilly and Company
Introduction to AMVUTTRA® (vutrisiran)”
12:30–1:15 p.m. | Learning Studio 2
Supporter: Alnylam Pharmaceuticals, Inc.
An Oral Treatment Option for Adults With Hypercholesterolemia
12:30–1:15 p.m. | Learning Studio 3
Supporter: Merck & Co., Inc.
Cardiovascular Outcomes in Patients at High CV Risk: Evidence From the Veaslius-CV Study
12:30–1:15 p.m. | Learning Studio 4
Supporter: Amgen Inc.
Helping Refine Cardiovascular Risk Assessment With Albuminuria and CKD Diagnosis
12:30–1:15 p.m. | Learning Studio 5
Supporter: Boehringer Ingelheim Pharmaceuticals, Inc
Personalized CAD Risk Assessment and Plaque Staging With the CCTA + Heartflow Platform
3:15–4 p.m. | Heart Theater 1
Supporter: Heartflow, Inc.
Lp(a): Test, Stratify and Manage Risk The Newest Science and Guidelines for Including Lp(a) in Clinical Practice
3:15–4 p.m. | Learning Studio 3
Supporter: Eli Lilly and Company
Monday, Nov. 9
Quantifying Coronary Inflammation, Redefining Risk: The Evidence, The Verdict, The Practice
9:30–10:15 a.m. | Learning Studio 3
Supporter: Caristo Diagnostics
A presentation sponsored by Eli Lilly and Company
11:15 a.m.–Noon | Learning Studio 1
Supporter: Eli Lilly and Company
Beyond Efficacy: Understanding the Barriers to Achieving LDL-C Goals and Optimizing Cardiovascular Risk Reduction
11:15 a.m.–Noon | Learning Studio 2
Supporter: AstraZeneca
